"Lilly had a solid start to the year, with 45% year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound," said David A. Ricks, Lilly chair and CEO. "Our pipeline continued to ...

He is speaking publicly for the first time about having the condition and using Mounjaro, in partnership with its manufacturer, Eli Lilly. The active ingredient in GLP-1s mimics a hormone of the ...

Stonestreet — alongside his mother Jamey — is now a spokesperson for Eli Lilly and Company, maker of Mounjaro. He admits that because the medication worked so well for him, he felt committed ...

Sales of Lilly's blockbuster weight-loss drugs Mounjaro and Zepbound rose to $3.84 billion and $2.31 billion, respectively. Mounjaro sales topped expectations of $3.76 billion and Zepbound fell ...

Eli Lilly LLY-3.25%decrease; red down pointing triangle revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged ...

Zepbound was ahead by $32 million while Mounjaro came in ahead by $70 million. Read more about Eli Lilly's stock moves and today's market action. Still, Eli Lilly holds the lead in the current ...

Lilly produces active pharmaceutical ingredients for some of its key medicines, like Zepbound and Mounjaro, in Ireland. Pharmaceutical exports from Ireland to the U.S. surged 450% in February ...

In the first quarter, top-line growth is expected to have been driven by demand growth for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine ...

In the first quarter, top-line growth is expected to have been driven by demand growth for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine ...